These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 23275363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK, DURATION-4 Study Group.
    Diabetes Care; 2012 Feb; 35(2):252-8. PubMed ID: 22210563
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T.
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [Abstract] [Full Text] [Related]

  • 9. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group.
    Ann Intern Med; 2005 Oct 18; 143(8):559-69. PubMed ID: 16230722
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T, Fövényi J, Faludi P, Han J, Macconell L, Wille S, Kiljanski J.
    Clin Ther; 2012 Jun 18; 34(6):1301-13. PubMed ID: 22608106
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH, 4B Study Group.
    Diabetes Care; 2014 Oct 18; 37(10):2763-73. PubMed ID: 25011946
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec 18; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).
    Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, Gerich JE.
    Diabetes Care; 2013 Oct 18; 36(10):2945-51. PubMed ID: 23698396
    [Abstract] [Full Text] [Related]

  • 18. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M, Van Gaal L, Guerci B, Stranks S, Han J, Malloy J, Boardman MK, Trautmann ME.
    Lancet Diabetes Endocrinol; 2014 Jun 18; 2(6):464-73. PubMed ID: 24731672
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.
    Ann Intern Med; 2011 Jan 18; 154(2):103-12. PubMed ID: 21138825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.